Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma, Version 2.2013 Featured Updates to the NCCN Guidelines

These NCCN Guidelines Insights highlight the important updates/changes specific to the management of Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma. These include the addition of regimens containing novel agents as primary and salvage therapy options, inclusion of the updated summary of response categories and criteria from the sixth international workshop on Waldenstrom's Macroglobulinemia, and a section on management of peripheral neuropathy in the accompanying discussion. (JNCCN 2012;10:1211-1218)